ATOS Research and Charts

ATOS - Atossa Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-16 (Delayed quote data 2025-04-04)

Last 0.60	Change ⇓ -0.04 (0.00%)	Volume 1,501,262
	Open 0.64	High 0.64	Low 0.60

8EMA (Daily) 0.66	40EMA (Daily) 0.75	50EMA (Daily) 0.78	STO (Daily) 9.913	MACD Hist (Daily) -0.013
8EMA (Weekly) 0.734	40EMA (Weekly) 1.02	50EMA (Weekly) 1.05	STO (Weekly) 8.453	MACD Hist (Weekly) -0.037


Company Profile
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.